CC
KALV

Corton Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Corton Capital’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-39,593
Closed -$466K – 579
2024
Q2 		$466K Buy
+39,593
New +$462K 0.24% 60
2022
Q1 		– Sell
-15,991
Closed -$212K – 454
2021
Q4 		$212K Buy
+15,991
New +$255K 0.09% 208

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Corton Capital's KALV Position: Q3 2024 in Review

Corton Capital sold out of KalVista Pharmaceuticals (KALV) in Q3 2024, closing a stake of 39,593 shares — an estimated $466K sold.

Corton Capital first reported a position in KALV in Q4 2021 and held it in 2 quarters. The position peaked at $466K in Q2 2024. 122 funds tracked by Wall St. Rank hold KALV as of Q3 2024.

  • Corton Capital reported no remaining KalVista Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Corton Capital sold 39,593 KalVista Pharmaceuticals shares in Q3 2024, an estimated $466K.
  • Corton Capital first reported a position in KalVista Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Corton Capital's KalVista Pharmaceuticals position peaked at $466K in Q2 2024.
  • 122 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2024.

Based on Corton Capital's 13F filing for Q3 2024, filed 14 Nov 2024.